-Roche and Genentech reach a friendly agreement to combine the two organizations
-Celgene expects lower growth in Q1 2009
-Arena's Lorcaserin is safe and effective in first Phase III trial
-BB BIOTECH shareholders approve all proposals submitted by the Board of Directors